Dr. Isaac Eliaz (www.dreliaz), whom the study authors acknowledge for his development of the Modified Citrus Pectin used in their most recent analysis, notes the importance of this new research, saying, "Androgen-dependent prostate cancer is the more common type of prostate cancer, and the one more often found in localized and less aggressive disease.  What is most significant is the ability of this specific type of MCP to induce apoptosis in androgen-independent prostate cancer cell lines, which is the more aggressive cancer that can metastasize and lead to death. Slowing down the progression of this cancer has a direct effect on prolonging the life of these individuals." 

"The anti-metastatic role of MCP is well established," continues Dr. Eliaz. "The fact that it can have a direct effect on the cancer itself makes it important in prevention, in early stage prostate cancer (which is usually hormonal sensitive-androgen dependent), and in later stage advanced prostate cancer. Its safety and the fact that it doesn't work via hormonal induced mechanisms of action makes it an excellent agent to be used in conjunction with other therapies."

Ongoing research on this MCP in prostate as well as breast cancer continues to show encouraging results, and additional studies are forthcoming.

"It's not a cure," Dr. Geo Espinosa explains, "but MCP has helped produce qualitative results for my patients, and as a direction, it is worth pursuing more research to see what else nature can provide to help us defeat cancer completely." 

www.modifiedcitruspectin 

SOURCE Better Health Publishing